Shockwave Medical Announces Positive Results for Intravascular Lithotripsy in Lower Limb Lesions at VIVA 2024
SHERIDAN, WYOMING – November 10, 2024 – Shockwave Medical, a Johnson & Johnson MedTech company and a global leader in circulatory restoration, announced positive 30-day results from its DISRUPT BTK II study. This post-market study evaluated the safety and effectiveness of the Shockwave Peripheral IVL System in treating calcified peripheral lesions below the knee (BTK), including patients with critical limb-threatening ischemia (CLTI).
Addressing Peripheral Artery Disease with IVL Technology